PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis
NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD
Taking everything into account, PLX scores 5 out of 10 in our fundamental rating. PLX was compared to 555 industry peers in the Biotechnology industry. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here. PLX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year PLX was profitable.
PLX had a negative operating cash flow in the past year.
In multiple years PLX reported negative net income over the last 5 years.
In the past 5 years PLX reported 4 times negative operating cash flow.
1.2 Ratios
PLX has a better Return On Assets (5.29%) than 92.43% of its industry peers.
The Return On Equity of PLX (8.64%) is better than 93.51% of its industry peers.
PLX has a better Return On Invested Capital (7.82%) than 94.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.29% | ||
| ROE | 8.64% | ||
| ROIC | 7.82% |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PLX's Profit Margin of 6.54% is amongst the best of the industry. PLX outperforms 91.71% of its industry peers.
With an excellent Operating Margin value of 7.74%, PLX belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
PLX has a Gross Margin of 49.97%. This is in the better half of the industry: PLX outperforms 76.58% of its industry peers.
In the last couple of years the Gross Margin of PLX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.74% | ||
| PM (TTM) | 6.54% | ||
| GM | 49.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
2. Health
2.1 Basic Checks
PLX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PLX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PLX has more shares outstanding
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -3.07, we must say that PLX is in the distress zone and has some risk of bankruptcy.
PLX's Altman-Z score of -3.07 is in line compared to the rest of the industry. PLX outperforms 47.39% of its industry peers.
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.07 |
ROIC/WACC0.85
WACC9.22%
2.3 Liquidity
A Current Ratio of 2.49 indicates that PLX has no problem at all paying its short term obligations.
With a Current ratio value of 2.49, PLX is not doing good in the industry: 69.91% of the companies in the same industry are doing better.
A Quick Ratio of 1.69 indicates that PLX should not have too much problems paying its short term obligations.
PLX has a Quick ratio of 1.69. This is in the lower half of the industry: PLX underperforms 79.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.49 | ||
| Quick Ratio | 1.69 |
3. Growth
3.1 Past
PLX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.00%.
The Revenue has been growing slightly by 0.18% in the past year.
Measured over the past years, PLX shows a decrease in Revenue. The Revenue has been decreasing by -0.48% on average per year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)0.18%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%169.68%
3.2 Future
The Earnings Per Share is expected to grow by 431.79% on average over the next years. This is a very strong growth
PLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.52% yearly.
EPS Next Y943.67%
EPS Next 2Y431.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year61.73%
Revenue Next 2Y59.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PLX is valuated quite expensively with a Price/Earnings ratio of 38.50.
Based on the Price/Earnings ratio, PLX is valued cheaply inside the industry as 93.33% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.45, PLX is valued a bit more expensive.
A Price/Forward Earnings ratio of 1.82 indicates a rather cheap valuation of PLX.
PLX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PLX is cheaper than 99.10% of the companies in the same industry.
PLX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.90.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.5 | ||
| Fwd PE | 1.82 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PLX is valued cheaply inside the industry as 94.95% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.32 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PLX's earnings are expected to grow with 431.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y431.79%
EPS Next 3YN/A
5. Dividend
5.1 Amount
PLX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.54
+0.04 (+2.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners11.2%
Inst Owner Change86.42%
Ins Owners4.18%
Ins Owner Change0%
Market Cap122.60M
Analysts80
Price Target14.28 (827.27%)
Short Float %1.67%
Short Ratio0.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-118.86%
Min EPS beat(2)-265.02%
Max EPS beat(2)27.3%
EPS beat(4)1
Avg EPS beat(4)-127.99%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)3
Avg EPS beat(8)-22.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-28.73%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)-3.82%
Revenue beat(4)2
Avg Revenue beat(4)-10.34%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)9.37%
Revenue beat(8)5
Avg Revenue beat(8)31.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.45%
PT rev (3m)-3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.5 | ||
| Fwd PE | 1.82 | ||
| P/S | 2.05 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.71 | ||
| P/tB | 2.71 | ||
| EV/EBITDA | 17.32 |
EPS(TTM)0.04
EY2.6%
EPS(NY)0.85
Fwd EY55.09%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.75
BVpS0.57
TBVpS0.57
PEG (NY)0.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.29% | ||
| ROE | 8.64% | ||
| ROCE | 9.34% | ||
| ROIC | 7.82% | ||
| ROICexc | 12.88% | ||
| ROICexgc | 12.88% | ||
| OM | 7.74% | ||
| PM (TTM) | 6.54% | ||
| GM | 49.97% | ||
| FCFM | N/A |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score4
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 74.55% | ||
| Cap/Sales | 1.66% | ||
| Interest Coverage | 6.04 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.49 | ||
| Quick Ratio | 1.69 | ||
| Altman-Z | -3.07 |
F-Score4
WACC9.22%
ROIC/WACC0.85
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y943.67%
EPS Next 2Y431.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.18%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%169.68%
Revenue Next Year61.73%
Revenue Next 2Y59.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.42%
OCF growth 3YN/A
OCF growth 5YN/A